Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that HER2-positive status confers therapeutic sensitivity to Carboplatin, Docetaxel, Pertuzumab, Trastuzumab in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab / trastuzumab (phesgo) in combination with carboplatin and docetaxel (TCHP) for reimbursement as a treatment option for the neoadjuvant treatment of HER2-positive locally advanced, inflammatory, or early breast cancer at high risk of recurrence in adult patients.
This statement is based on a regulatory approval from the Health Service Executive:
Neoadjuvant treatment of adult patients with HER2-positive locally advanced, inflammatory or early breast cancer at high risk of recurrence.